- Home
- CGBD vs SPRY Comparison
CGBD vs SPRY Comparison
Compare CGBD & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGBD
- SPRY
- Stock Information
- Founded
- CGBD 2012
- SPRY 2015
- Country
- CGBD United States
- SPRY United States
- Employees
- CGBD N/A
- SPRY N/A
- Industry
- CGBD Finance: Consumer Services
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- CGBD Finance
- SPRY Health Care
- Exchange
- CGBD Nasdaq
- SPRY Nasdaq
- Market Cap
- CGBD 940.7M
- SPRY 1.1B
- IPO Year
- CGBD 2017
- SPRY N/A
- Fundamental
- Price
- CGBD $17.88
- SPRY $11.24
- Analyst Decision
- CGBD Hold
- SPRY Strong Buy
- Analyst Count
- CGBD 3
- SPRY 4
- Target Price
- CGBD $17.00
- SPRY $26.00
- AVG Volume (30 Days)
- CGBD 205.3K
- SPRY 1.2M
- Earning Date
- CGBD 02-25-2025
- SPRY 03-20-2025
- Dividend Yield
- CGBD 10.46%
- SPRY N/A
- EPS Growth
- CGBD 29.39
- SPRY N/A
- EPS
- CGBD 1.72
- SPRY N/A
- Revenue
- CGBD $238,921,000.00
- SPRY $2,568,000.00
- Revenue This Year
- CGBD N/A
- SPRY $68,783.34
- Revenue Next Year
- CGBD $4.63
- SPRY $503.87
- P/E Ratio
- CGBD $10.37
- SPRY N/A
- Revenue Growth
- CGBD 1.68
- SPRY 8460.00
- 52 Week Low
- CGBD $15.01
- SPRY $7.55
- 52 Week High
- CGBD $18.74
- SPRY $18.51
- Technical
- Relative Strength Index (RSI)
- CGBD 47.12
- SPRY 37.72
- Support Level
- CGBD $17.06
- SPRY $11.58
- Resistance Level
- CGBD $18.50
- SPRY $12.43
- Average True Range (ATR)
- CGBD 0.26
- SPRY 0.72
- MACD
- CGBD -0.04
- SPRY -0.14
- Stochastic Oscillator
- CGBD 55.59
- SPRY 0.53
About CGBD Carlyle Secured Lending Inc.
Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.